FFA
TEVA icon

Frazier Financial Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Frazier Financial Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37
Closed -$1.11K – 831
2026
Q1 		$1.11K Buy
+37
New +$1.19K ﹤0.01% 615
2024
Q3 		– Sell
-37
Closed -$602 – 1033
2024
Q2 		$602 Buy
+37
New +$570 ﹤0.01% 890
2024
Q1 		– Sell
-500
Closed -$5.22K – 1001
2023
Q4 		$5.22K Buy
+500
New +$4.67K ﹤0.01% 484

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Frazier Financial Advisors's TEVA Position: Q2 2026 in Review

Frazier Financial Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 37 shares — an estimated $1.11K sold.

Frazier Financial Advisors first reported a position in TEVA in Q4 2023 and held it in 3 quarters. The position peaked at $5.22K in Q4 2023. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Frazier Financial Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Frazier Financial Advisors sold 37 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.11K.
  • Frazier Financial Advisors first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Frazier Financial Advisors's Teva Pharmaceuticals position peaked at $5.22K in Q4 2023.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Frazier Financial Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.